bims-myxlip Biomed News
on Myxoid liposarcoma
Issue of 2022‒05‒29
one paper selected by
Laura Mannarino
Humanitas Research

  1. Oncol Res Treat. 2022 May 24.
      BACKGROUND: While soft tissue sarcomas (STSs) are rare tumors, liposarcomas are among the most common type of STS and are divided into four main subtypes: atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDLPS); dedifferentiated liposarcoma (DDLPS); myxoid/round cell liposarcoma (MLPS); and pleomorphic liposarcoma (PLPS). The four different subtypes of liposarcomas have varying underlying molecular pathology, clinical behavior, and treatment sensitivity.SUMMARY: Surgical resection is the mainstay of treatment for patients with localized liposarcoma. Radiotherapy is often used in conjunction with surgery for improving local control of liposarcoma, with MLPS being the most radiosensitive of the four subtypes. For unresectable, advanced, or metastatic disease, the effectiveness of chemotherapy can vary by subtype, with MLPS and PLPS being considered to be chemo-sensitive; however, median survival is low at around 2-years. Current first-line treatment options for patients with liposarcoma include local treatment with or without doxorubicin, ifosfamide, or a doxorubicin-ifosfamide combination; while second-line (and beyond) treatment options include ifosfamide, gemcitabine-based combinations, trabectedin, eribulin and possibly pazopanib as established therapies. A number of other experimental treatment options are being evaluated, including mouse double minute 2 homolog (MDM2) inhibitors, cyclin-dependent kinase (CDK)4/6 inhibitors, immune checkpoint modulators, nuclear export inhibitors, multi-kinase inhibitors, peroxisome proliferator-activated receptor gamma (PPARγ) agonists, or various combinations regimens. This review discusses established systemic therapies and experimental treatment options for the treatment of patients with liposarcoma.
    KEY MESSAGE: New treatments are needed to effectively treat liposarcomas. Results from emerging and ongoing experimental therapeutic options will further define the role that these new treatments will play in the management of the different subtypes of liposarcoma.